FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma

[FDA]

On January 25, 2022, the Food and Drug Administration approved tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.


Baca selengkapnya di : http://www.fda.gov...